# MDimune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mdimune

- Industry: Pharmaceuticals
- Headquarters: South Korea
- Website: www.mdimune.com
- Total disclosed funding: $13M
- Latest round: Series B (Aug 27, 2019)
- Investors on record: 6

## About

Based in Seoul, South Korea, founded in 2015 by Seung Wook Oh and Shingyu Bae, MDimune, trading under the name MDimune Inc., operates as a smart drug delivery platform that focuses on developing anticancer therapeutics through BioDrone by addressing other diseases including osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative diseases. In August 2019, MDimune raised KRW 10.7 billion in series B funding from DAYLI Partners, InterValue Partners, KClavis Investment, etc. 

MDimune Inc. is a platform that has been developed by the designer of a drug delivery system designed for accurate administration of strong drugs to specified areas. The company's platform provides vesicles derived from immune or stem cells to biotechnology and pharmaceutical companies, facilitating the development of novel treatments that carry various medications to the intended region. This enables physicians to provide vesicle-based anticancer drugs to their patients.

## Funding rounds

- Series B, Aug 27, 2019, $9.7M — STIC Investments, The Wells Investment, Quad Asset Management, InterValue Partners, DAYLI Partners, KClavis Investment
- Series A, Oct 1, 2018, $3.8M — STIC Investments, DAYLI Partners

## Investors

- STIC Investments (https://capitalatlas.ai/funds/stic-investments) — Series A, Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A, Series B
- The Wells Investment (https://capitalatlas.ai/funds/the-wells-investment) — Series B
- Quad Asset Management — Series B
- InterValue Partners (https://capitalatlas.ai/funds/intervalue-partners) — Series B
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series B